# Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

> **NCT03443674** · PHASE1 · COMPLETED · sponsor: **Clover Biopharmaceuticals AUS Pty** · enrollment: 7 (actual)

## Conditions studied

- Peritoneal Malignancies

## Interventions

- **DRUG:** SCB-313

## Key facts

- **NCT ID:** NCT03443674
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-18
- **Primary completion:** 2021-05-30
- **Final completion:** 2021-08-26
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443674, "Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03443674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*